• RAPTIVA was approved by the FDA in October, 2003 for the treatment of moderate to severe plaque psoriasis and is manufactured by Genentech.

• The psoriasis drug RAPTIVA received a “black box” warning, the FDA’s sternest warning, on October 16, 2008, about the risk of life-threatening infections including a rare brain infection and meningitis following the deaths of three patients using the psoriasis drug efalizumab, which is marketed as RAPTIVA. Further, European regulators have recommended suspension of sales of Genentech Inc.’s psoriasis treatment RAPTIVA.

• Patients taking RAPTIVA should watch for signs of serious infection including confusion, loss of balance or dizziness, difficulty walking or talking and vision problems, bruising, worsening of psoriasis or arthritis, sudden onset of tingling, numbness, or weakness in the leg, arms, or face.
  

• If you or a loved one has taken RAPTIVA (efalizumab) and suffered a life-threatening infection or death as a result of a side effect of RAPTIVA, you may have a legal claim.

FOR MORE INFORMATION AND FOR A FREE CONSULTATION  CALL ANYTIME (24 HOURS A DAY)